abstract |
The present disclosure uses GDF-15 as a safety biomarker to determine the toxicological effects of Mdm2 inhibitors, particularly a dose of Mdm2 for determining the toxicological effects of Mdm2 inhibitors in a subject. There are ex vivo methods for determining the likelihood of developing thrombocytopenia in a subject in response to administration of an inhibitor, methods of using an Mdm2 inhibitor in the treatment of cancer in a subject, and patients with cancer Kits for use in predicting the likelihood of developing thrombocytopenia in response to treatment with a dose of an Mdm2 inhibitor, kits for use in treating patients with cancer and related disclosures It relates to an embodiment. |